In order to select drug candidates for screening in combination with KPT-330 in our in vitro AML experimental model, we hypothesized that proteins co-overexpressed with CRM1 in patients with AML, as well as in other tumour types, would represent pro-tumoral pathways co-activated with CRM1 and, therefore, relevant targets for putatively synergistic KPT-330-based combination treatments. Here, XPO1 is linked to neoplasm.